Benzinga | Sep 10, 2020 08:15AM EDT

Mersana Therapeutics To Present Updated Interim Data From Ovarian Cancer Cohort Of The XMT-1536 Phase 1 Expansion Study At The 2020 ESMO Virtual Congress

-Company to Host Conference Call and Webcast Featuring Study Investigator,Erika Hamilton, MD on September 17, 2020 at 8:00 a.m. ET -



CAMBRIDGE, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need,today announced that it will present updated interim data from the ovarian cancer cohort of the ongoing Phase 1 expansion study evaluating XMT-1536, its first-in-class ADC candidate targeting NaPi2b. These data will be presented in an on-demand e-poster display at the 2020 European Society of Medical Oncology (ESMO) Virtual Congress and will be available beginning Thursday, September 17, 2020.

Details of the e-poster display are as follows:

Poster Title:Safety and Efficacy of XMT-1536 in Ovarian Cancer: A Subgroup Analysis from the Phase I Expansion Study of XMT-1536, a NaPi2b Antibody-Drug Conjugate

Abstract Number: 2365

Presentation Number: 836P

E-poster Available:Thursday, September 17, 2020 at 9:00 a.m. CEST (3:00 a.m. ET)

Mersana will also host a live conference call and webcast featuring study investigator,Erika Hamilton, MD, Director of the Breast Cancer and Gynecologic Cancer Research Program from theSarah Cannon Research Instituteat Tennessee Oncology on Thursday, September 17, 2020 at 8:00 a.m. ET. To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 5731456.A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com.